Immediate Impact
67 standout
Citing Papers
Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs
2024 Standout
The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
2024 Standout
Works of Christopher Sweeney being referenced
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
2011
Abstract A107: Clinical trial combining proteasome (NPI-0052) and HDAC (vorinostat) inhibition in melanoma, pancreatic, and lung cancer
2009
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Christopher Sweeney | 154 | 96 | 73 | 139 | 51 | 347 | |
| C. Massard | 127 | 84 | 40 | 137 | 38 | 317 | |
| Ambrus Jl | 67 | 93 | 24 | 95 | 49 | 402 | |
| Tso‐Fu Wang | 64 | 82 | 30 | 122 | 46 | 394 | |
| Takuto Hara | 223 | 92 | 71 | 82 | 68 | 322 | |
| Letizia Laera | 173 | 117 | 51 | 99 | 32 | 317 | |
| Huimin Ma | 59 | 77 | 23 | 152 | 41 | 368 | |
| Simona Borštnar | 73 | 149 | 24 | 89 | 42 | 341 | |
| Yonghong Dang | 94 | 95 | 118 | 51 | 31 | 387 | |
| Maria Banci | 72 | 65 | 139 | 102 | 32 | 382 | |
| Larry L. Schenken | 92 | 136 | 133 | 89 | 34 | 410 |
All Works
Loading papers...